• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奎宁在荷兰用于疟疾治疗与控制的情况。

The use of quinine for treatment and control of malaria in The Netherlands.

作者信息

Verhave J P

机构信息

Faculty of Medical Sciences, University of Nijmegen, The Netherlands.

出版信息

Trop Geogr Med. 1995;47(6):252-8.

PMID:8650735
Abstract

The manufacturing of quinine in The Netherlands began shortly after 1820; large scale production started with the foundation of the Amsterdam Chinine Factory in 1881. The quantity of sold quinine in the Province of North-Holland leads retrospectively to the conclusion that an epidemic of malaria had occurred around 1880. At the start of a new epidemic in 1899, it was demonstrated that quinine killed the bloodforms of tertian malaria immediately. However, 50% of the patients experienced a relapse, particularly after interruption of treatment. The length--f the course did not change the chance of relapse. With the beginning of another epidemic in 1919, scientific work and education of the people started in an organized fashion and patients were urged to use quinine only at the prescription of physicians. Because of the inability to prevent relapses, an alternative to quinine was badly needed. In 1930 plasmochin became available, which proved to be useful in combination with quinine. It was not until 1934 that the asymptomatic carriers were recognized as a problem for control because their unobserved parasitic relapses were considered a major source of infection for mosquitoes. In 1939 it was proposed to apply autumnal quininization, which meant a scrupulous screening of the population. The early forties brought yet another major epidemic. Both quinine and Quiniplex were used until the fifties, when endemic malaria disappeared. The new schizonticidal drugs came too late to challenge the primate of quinine in the era of temperate zone Plasmodium vivax in The Netherlands.

摘要

1820年后不久,荷兰便开始生产奎宁;1881年阿姆斯特丹奎宁工厂成立,大规模生产由此开始。回顾北荷兰省奎宁的销售数量可得出结论,1880年左右曾发生过疟疾流行。1899年新一轮疫情开始时,已证实奎宁可立即杀死间日疟的血内原虫。然而,50%的患者出现复发,尤其是在治疗中断后。疗程长短并未改变复发几率。1919年另一轮疫情开始时,科学工作和民众教育有组织地开展起来,同时敦促患者仅在医生处方下使用奎宁。由于无法预防复发,急需一种替代奎宁的药物。1930年扑疟喹啉问世,事实证明它与奎宁联合使用很有用。直到1934年,无症状携带者才被视为控制方面的一个问题,因为他们未被察觉的寄生虫复发被认为是蚊子感染的主要来源。1939年有人提议采用秋季奎宁疗法,这意味着要对人群进行严格筛查。20世纪40年代初又出现了一次大流行。在20世纪50年代地方性疟疾消失之前,奎宁和复方奎宁都一直在使用。在荷兰温带地区间日疟流行的时代,新型裂殖体杀灭药物出现得太晚,无法挑战奎宁的首要地位。

相似文献

1
The use of quinine for treatment and control of malaria in The Netherlands.奎宁在荷兰用于疟疾治疗与控制的情况。
Trop Geogr Med. 1995;47(6):252-8.
2
[The history of malaria in Sã Tomé. Considerations on an epidemic].[圣多美疟疾史。关于一场流行病的思考]
Acta Med Port. 1996 Jul-Sep;9(7-9):259-65.
3
Quinine (Cinchona) and the incurable malaria: India c. 1900-1930s.奎宁(金鸡纳)与无法治愈的疟疾:约1900年至20世纪30年代的印度
Parassitologia. 2000 Jun;42(1-2):91-100.
4
[Current malaria situation in Turkmenistan].[土库曼斯坦当前的疟疾形势]
Med Parazitol (Mosk). 2001 Jan-Mar(1):37-9.
5
[Malaria therapy: quinine again in style].[疟疾治疗:奎宁再度流行]
Dtsch Med Wochenschr. 1968 May 3;93(18):926-8.
6
Sappington's anti-fever pills and the Westward migration.萨平顿的退烧药与西进运动。
Trans Am Clin Climatol Assoc. 1968;79:34-44.
7
[A history of malaria in modern Korea 1876-1945].[现代韩国(1876 - 1945年)的疟疾史]
Uisahak. 2011 Jun 30;20(1):53-82.
8
[Editorial note: Italian antimalarial legislation, with particular reference to the State's quinine laws].[编辑说明:意大利抗疟疾立法,特别提及国家的奎宁法]
Parassitologia. 2003 Dec;45(3-4):155-6.
9
East meets West: how China almost cured malaria.东方与西方的交汇:中国几乎攻克疟疾的历程
Endeavour. 2008 Sep;32(3):101-6. doi: 10.1016/j.endeavour.2008.07.001. Epub 2008 Aug 8.
10
Quinine: the conquest of malaria and the beginning of the modern drug industrial complex.奎宁:疟疾的攻克与现代制药产业联合体的开端。
W V Med J. 1999 Mar-Apr;95(2):64-5.